Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

Caitlin E. Cox

December 29, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

Shelley Wood

April 02, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

Advertisement

June 2024 Dispatch for the CV Team

Bempedoic Acid Gains CV Risk Reduction Indication

TCTMD’s Top 10 Most Popular Stories for December 2023

FDA Approves Colchicine for Decreasing CV Events

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

TCTMD’s Top 10 Most Popular Stories for December 2021

British Medical Groups Express Concern About Inclisiran Rollout

TCTMD’s Top 10 Most Popular Stories for March 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Approves Evinacumab for Rare Homozygous FH

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content